ReNeuron Group plc
RNUGF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$62.89K
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $62,891.00 |
|---|---|
| Enterprise Value | - |
| Earnings per Share | $-0.09 |
| Beta | 1.04 |
| Outstanding Shares | 57,173,760 |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | -0.01 |
|---|---|
| PEG | 0.08 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | - |
| Debt to Equity | - |
Revenue Sources
No data
Next Earnings Call
Expected Date
November 11, 2026
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About ReNeuron Group plc
26 employees
CEO: Iain Gladstone Ross
ReNeuron Group plc is a UK-based biotechnology firm dedicated to the discovery, advancement, and eventual market launch of cutting-edge cell-based medical treatments. Their current pipeline features a CTX stem cell therapy, designed to i...